Novel Therapeutic Nanobody
Reactivates p53. Destroys cancer.*
Our Focus
Targeting the Most Aggressive Cancers
- Breast cancer causes ~670,000 deaths annually with 2.3 million new cases worldwide (WHO).
- Triple-negative breast cancer (TNBC) is highly aggressive, with lower survival rates and few targeted treatment options.
- Our lead candidate, PHP53-nb kills cancer cells by reactivating mutant p53, addressing a key driver of TNBC.
- PHP53-nb is a patented nanobody with no linkers that internalizes within cancer cells initiating the reactivation of p53 protein leading to apoptosis.
Mechanism of Action
PHP53-nb is a nanobody which specifically targets cancer cells. It:
Enters the cell through endocytosis
Re-activates p53 resulting in apoptosis of cancer cells
Featured Data
PHP53-nb reduces cell viability in a dose dependent manner in both triple negative breast cancer (TNBC) (pink) and ovarian (teal) tumor cell models. Go to our science page to see how PHP53-nb reduces cell viability in other types of cancers.
Our Platform and Pipeline
Our nanobody platform can be used for a variety of therapeutic applications and has several advantages over traditional monoclonal antibodies.
Multi-indication Payload: 3-NAntC Peptide (TNBC)
Therapeutic Humanized Camelid Nanobody: GEN01-AD
Therapeutic Humanized Camelid Nanobody: PHP53-nb (TNBC & other cancers)
Discovery
Preclinical
Phase 1
About PHP Biotech
A team of dedicated experts pushing what’s possible in cancer treatment
We are a US-based biotech company founded by innovative healthcare entrepreneurs and powered by a world-class scientific & research team, global CROs and CDMOs, who specialize in nanobody and translational biotechnology and are instrumental in our critical research.
Our lead candidate, PHP53-nb, is a first-in-class humanized nanobody showing strong anti-tumor efficacy, low toxicity, and a novel mechanism of action.
